insights_auto
Why is AXGN down 5.06%?
Dive Deeperchevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
$48.75
arrow_downward
-5.06%(-2.60) 1D
$48.55
arrow_downward
-0.41% (-0.20)todayPre-market
Closed: Nov 5, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
$51.62
High
$51.85
Low
$47.57
Mkt. cap
2.91B
Avg. vol.
1.78M
Volume
375.00
52-wk high
$52.91
52-wk low
$23.00
EPS
-$0.68
Beta
1.21
Shares outstanding
59.73M
No. of employees
622
Open
$51.62
High
$51.85
Low
$47.57
Mkt. cap
2.91B
Avg. vol.
1.78M
Volume
375.00
52-wk high
$52.91
52-wk low
$23.00
EPS
-$0.68
Beta
1.21
Shares outstanding
59.73M
No. of employees
622
News stories
From web sources and news partners
MarketForces Africa
·
54 minutes ago
Global Markets Tumble On Tech Stocks Rout, Nasdaq, S&P 500 Fall
Trefis
·
1 hour ago
S&P 500 Or Dividend Stocks: What Mix Fits Your Plan For 2027?
Benzinga
·
42 minutes ago
Stock Market Today: Dow Jones, S&P 500 Futures Trade Mixed Ahead of October's Jobs Report— Airbnb, Cloudf
TradingView
·
6 hours ago
S&P 500 clings to 200-Day SMA as support zone comes into focus
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Florida, United States
SectorHealth Care
IndustryMedical device
Websiteaxogeninc.com